WO1993002107A1 - Immunoglobulin-combining artificial protein - Google Patents
Immunoglobulin-combining artificial protein Download PDFInfo
- Publication number
- WO1993002107A1 WO1993002107A1 PCT/JP1992/000938 JP9200938W WO9302107A1 WO 1993002107 A1 WO1993002107 A1 WO 1993002107A1 JP 9200938 W JP9200938 W JP 9200938W WO 9302107 A1 WO9302107 A1 WO 9302107A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- igg
- binding
- immunoglobulin
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
Definitions
- the linked protein obtained in this manner (hereinafter sometimes referred to as a linked protein) is more specific for IgG than native protein A. It was discovered that the binding ability was excellent, and further research was carried out based on these new findings, thereby completing the present invention.
- One AB domain consists of 116 amino acids, and its molecular weight is
- n Number of linked AB domains
- a carrier cyan bromide activated Sepharose 4 ⁇ , manufactured by Pharmacia
- ImMHC1 ImM hydrochloride
- lmM HC1 200 ml per lg dry gel
- mosquito Tsu pre Nguno, 'Tsu off ⁇ chromatography [0.1M NaHC0 3 (P H8.3) -0.5M NaCl ] at, this was washed (dry gel 1 g per Ri 5 ml).
- the ligand protein ligated protein produced in Example 1: repeated AB domain
- the column After adding ( ⁇ . ⁇ ⁇ ) and keeping at room temperature for 2 hours, the column is subjected to force buffering, 0.1 M acetate buffer ( ⁇ 4) -0.5 ⁇ NaCl, and then coupling buffer.
- the column was washed in a tilted manner to prepare columns each filled with a carrier on which various kinds of linked proteins were immobilized.
- any Purotei emissions A also binding rate to the carrier may, for example, binding rate to support PR0T-AB 4 was filed at about 95%.
- FIG. 5 shows the measurement results of the binding capacity of IgG for each of the ligated proteins and commercially available native protein A.
- the results clearly show that the protein binding of the conjugated protein increases as the number of ligated IgG-binding domains increases, for example, PROT-AB IV has about 35% of the binding capacity of the control. It was demonstrated that the purification purity was very high.
- the rabbits purified by PROT-AB IV-Sepharose column were applied to SDS-PAGE at a ratio of 4 g on SDS-PAGE, and the resulting patterns are shown in FIG.
- 1 is a molecular weight marker
- 2 is a rabbit anti-human CRP serum (8 ⁇ g)
- 3 is a purified IgG (4 g )
- the target IgG is concentrated as is clear from Fig. 6. This, in turn, resulted in a very high degree of purification, demonstrating clearly that this was the case.
- n number of D domain links
- each of these ligated proteins also had excellent IgG purification ability, as in Example 2 relating to the AB domain.
- linked proteins having various molecular weights can be freely prepared according to the purpose.
- the IgG-binding domain of protein A includes A,
- Lane M is a molecular weight marker of BRL
- Lanes 1 to 6 are a mixture of 1 ⁇ 81 to 1 according to the present invention
- Lane 7 is a mixture of Lanes 1 to 6. It can be clearly seen that lanes 1 to 7 have the desired predetermined molecular weight.
- Each marker-protein when the D domain obtained in Example 3 is used as a unit is defined as a molecular weight marker.
- marker proteins having various molecular weights can be freely prepared according to the purpose.
- the IgG binding domain of protein A includes E, C in addition to A, B, and D described above. Subordinate
- the target marker protein can be used for the E and C domains in the same or different domains. It can be prepared freely between India.
- the present invention is to produce an immunoglobulin-binding artificial protein having excellent IgG purification ability by utilizing a genetic engineering technique, and by selecting and binding each domain. It is possible to freely produce industrially linked proteins with the desired precise molecular weights, all of which have superior IgG G separation and purification capabilities compared to native protein A. It is shown.
- the present invention it is possible to efficiently separate and purify IgG, which plays an important role in each field of biotechnology, and to efficiently produce purified high-purity IgG. And can be. Further, according to the present invention, only IgG can be selectively separated and removed from a sample, and further, the present invention can be used for accurate and simple bioassay of IgG in a sample. .
- the present invention is to produce a marker protein by utilizing a genetic engineering technique, and to select and bind each domain to obtain a desired accurate molecular weight. Marker protein can be produced freely.
- the molecular weight marker for western blotting obtained by the present invention is not limited to the immunoblotting method, but can be used in the ADS SDS-polyacrynorea midgel electrophoresis method. Can be widely used even with general molecular weight
- Name and address of the depositary institution that deposited the microorganism The name of the depositary institution at the depositary institution 1-3-1, Higashi 1-chome, Tsukuba, Ibaraki, Japan 305
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69230061T DE69230061T2 (de) | 1991-07-25 | 1992-07-23 | Künstliches immunoglobulin-bindendes protein |
EP92916247A EP0550771B1 (en) | 1991-07-25 | 1992-07-23 | Immunoglobulin-binding artificial protein |
US08/406,809 US5580788A (en) | 1991-07-25 | 1995-03-20 | Use of immunoglogulin-binding artificial proteins as molecular weight markers |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3/207150 | 1991-07-25 | ||
JP3207150A JP2519136B2 (ja) | 1991-07-25 | 1991-07-25 | 分子量マ−カ− |
JP3/235687 | 1991-08-23 | ||
JP3235687A JP2584697B2 (ja) | 1991-08-23 | 1991-08-23 | IgG精製用組換え型プロテインA |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993002107A1 true WO1993002107A1 (en) | 1993-02-04 |
Family
ID=26516088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/000938 WO1993002107A1 (en) | 1991-07-25 | 1992-07-23 | Immunoglobulin-combining artificial protein |
Country Status (4)
Country | Link |
---|---|
US (1) | US5580788A (ja) |
EP (2) | EP0863210A3 (ja) |
DE (1) | DE69230061T2 (ja) |
WO (1) | WO1993002107A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039141A1 (en) * | 2006-09-29 | 2008-04-03 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain c from staphyloccocus aureus protein a for antibody isolation |
US7691608B2 (en) | 2006-12-06 | 2010-04-06 | Repligen Corporation | Nucleic acids encoding recombinant protein A |
US10189891B2 (en) | 2012-03-28 | 2019-01-29 | Ge Healthcare Bioprocess R&D Ab | Affinity chromatography matrix |
RU2701695C2 (ru) * | 2014-11-17 | 2019-09-30 | ДжиИ Хелткер Биопроцесс АрЭндДи АБ | Мутантные иммуноглобулин-связывающие полипептиды |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7563594A (en) * | 1993-08-23 | 1995-03-21 | Applied Immune Sciences, Inc. | Chimeric receptor containing one igg binding domain of both protein a and protein g |
JPH1073569A (ja) * | 1996-08-30 | 1998-03-17 | Oriental Yeast Co Ltd | 蛋白の測定 |
EP1911841B1 (en) * | 1997-01-08 | 2015-06-03 | Life Technologies Corporation | Methods for production of proteins |
DE69839553D1 (de) | 1997-01-08 | 2008-07-10 | Invitrogen Corp | Verfahren zur herstellung von proteinen |
DE19729248C1 (de) * | 1997-07-09 | 1998-07-09 | Jochen Uhlenkueken | Standardprotein |
GB9823071D0 (en) * | 1998-10-21 | 1998-12-16 | Affibody Technology Ab | A method |
US20040014082A1 (en) * | 2000-08-11 | 2004-01-22 | Invitrogen Corporation | Highly homogeneous molecular markers for electrophoresis |
SE0200943D0 (sv) | 2002-03-25 | 2002-03-25 | Amersham Biosciences Ab | Mutant protein |
US7781173B2 (en) * | 2003-09-25 | 2010-08-24 | Life Technologies Corporation | Homogeneous populations of molecules |
SE0400274D0 (sv) * | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
US20060023808A1 (en) * | 2004-05-17 | 2006-02-02 | Hajivandi Mahbod R | Compositions, kits, and methods for calibration in mass spectrometry |
WO2005114220A2 (en) * | 2004-05-17 | 2005-12-01 | Invitrogen Corporation | Compositions, kits, and methods for calibration in mass spectrometry |
EP2069386A4 (en) | 2006-07-21 | 2009-10-28 | Life Technologies Corp | PROTEIN MOLECULAR WEIGHT STANDARDS WITH HIGH DISINFECTION |
JP5522723B2 (ja) | 2007-05-21 | 2014-06-18 | ノマディックバイオサイエンス株式会社 | 新規ポリペプチド,アフィニティークロマトグラフィー用材,及びイムノグロブリンの分離及び/又は精製方法 |
US8592555B2 (en) | 2008-08-11 | 2013-11-26 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
SG162687A1 (en) | 2008-12-24 | 2010-07-29 | Millipore Corp | Caustic stable chromatography ligands |
SG10201604559TA (en) | 2011-06-08 | 2016-07-28 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
CN102507958A (zh) * | 2011-11-16 | 2012-06-20 | 江苏星驰生物科技有限公司 | 一种IgG含量的检测方法 |
US9657055B2 (en) * | 2011-11-30 | 2017-05-23 | Ge Healthcare Bioprocess R&D Ab | Affinity chromatography matrix |
EP3042912A4 (en) * | 2013-09-04 | 2017-05-03 | Protenova Co., Ltd. | Immunoglobulin-binding domain multimer |
JP2020504172A (ja) | 2016-12-12 | 2020-02-06 | フラー エス.アー.エール.エル. | 免疫グロブリン結合ポリペプチドおよびオリゴペプチドの免疫グロブリン結合容量を増加するための組成物および方法 |
US11028124B2 (en) | 2018-05-07 | 2021-06-08 | Repligen Corporation | Methods, devices and systems for 3-stage filtration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59501693A (ja) * | 1982-08-23 | 1984-10-11 | ファーマシア バイオテック エイビイー | 組換えdna分子及びその製造方法 |
JPS6460388A (en) * | 1987-05-08 | 1989-03-07 | Sekisui Chemical Co Ltd | Gene coding linked material of protein a-like substance fc bond region, recombinant plasmid containing said gene and transformant produced by using said recombinant plasmid |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507233A (en) * | 1981-04-22 | 1985-03-26 | Oriental Yeast Co., Ltd. | Colored molecular weight marker |
JPS5950163A (ja) * | 1982-09-14 | 1984-03-23 | Nec Corp | プラスチツクスの無電解銅メツキ方法 |
US5151350A (en) * | 1982-10-27 | 1992-09-29 | Repligen Corporation | Cloned genes encoding recombinant protein a |
SE8505921D0 (sv) * | 1985-12-13 | 1985-12-13 | Kabigen Ab | A method to export gene products to the growth medium of gram negative bacteria |
GB2188322A (en) * | 1986-03-26 | 1987-09-30 | Bayer Ag | Aprotinin and analogues thereof produced by a recombinant host |
US5084559A (en) * | 1987-03-27 | 1992-01-28 | Repligen Corporation | Protein a domain mutants |
WO1989010974A1 (en) * | 1988-05-11 | 1989-11-16 | Trustees Of The Sisters Of Charity Of Australia | Enzyme immunoassay system |
WO1992009633A1 (en) * | 1990-11-26 | 1992-06-11 | Public Health Laboratory Service Board | Immunoglobulin-binding proteins and recombinant dna molecules coding therefor |
-
1992
- 1992-07-23 DE DE69230061T patent/DE69230061T2/de not_active Expired - Lifetime
- 1992-07-23 EP EP97122254A patent/EP0863210A3/en not_active Withdrawn
- 1992-07-23 WO PCT/JP1992/000938 patent/WO1993002107A1/ja active IP Right Grant
- 1992-07-23 EP EP92916247A patent/EP0550771B1/en not_active Expired - Lifetime
-
1995
- 1995-03-20 US US08/406,809 patent/US5580788A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59501693A (ja) * | 1982-08-23 | 1984-10-11 | ファーマシア バイオテック エイビイー | 組換えdna分子及びその製造方法 |
JPS6460388A (en) * | 1987-05-08 | 1989-03-07 | Sekisui Chemical Co Ltd | Gene coding linked material of protein a-like substance fc bond region, recombinant plasmid containing said gene and transformant produced by using said recombinant plasmid |
Non-Patent Citations (4)
Title |
---|
Journal of Biological Chemistry, Vol. 259, No. 3, 1984, M. UHLEN et al. "Complete sequence of the staphylococcal gene encoding protein A", pages 1695-1702. * |
Protein Engineering, Vol. 1, No. 2, 1987, B. NILSSON et al. "A synthetic IgG-binding domain based on staphylococcal protein A", pages 107-113. * |
Protein Engineering, Vol. 2, No. 6, 1989, A. SAITO et al. "High level expression of a synthetic gene coding of IgG-binding domain B of staphylococcal protein A", pages 481-487. * |
See also references of EP0550771A4 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008039141A1 (en) * | 2006-09-29 | 2008-04-03 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain c from staphyloccocus aureus protein a for antibody isolation |
US8329860B2 (en) | 2006-09-29 | 2012-12-11 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US8772447B2 (en) | 2006-09-29 | 2014-07-08 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain C from staphylococcus aureus protein A for antibody isolation |
US9663559B2 (en) | 2006-09-29 | 2017-05-30 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US10213765B2 (en) | 2006-09-29 | 2019-02-26 | GE Healthcare Bioprocess R&D | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US10343142B2 (en) | 2006-09-29 | 2019-07-09 | Ge Healthcare Bioprocess R&D Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US10875007B2 (en) | 2006-09-29 | 2020-12-29 | Cytiva Bioprocess R&D Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US11517879B2 (en) | 2006-09-29 | 2022-12-06 | Cytiva Bioprocess R&D Ab | Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation |
US7691608B2 (en) | 2006-12-06 | 2010-04-06 | Repligen Corporation | Nucleic acids encoding recombinant protein A |
US10189891B2 (en) | 2012-03-28 | 2019-01-29 | Ge Healthcare Bioprocess R&D Ab | Affinity chromatography matrix |
RU2701695C2 (ru) * | 2014-11-17 | 2019-09-30 | ДжиИ Хелткер Биопроцесс АрЭндДи АБ | Мутантные иммуноглобулин-связывающие полипептиды |
Also Published As
Publication number | Publication date |
---|---|
DE69230061D1 (de) | 1999-11-04 |
DE69230061T2 (de) | 2000-01-05 |
EP0550771B1 (en) | 1999-09-29 |
US5580788A (en) | 1996-12-03 |
EP0863210A2 (en) | 1998-09-09 |
EP0550771A1 (en) | 1993-07-14 |
EP0550771A4 (en) | 1996-05-29 |
EP0863210A3 (en) | 1999-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993002107A1 (en) | Immunoglobulin-combining artificial protein | |
Sørensen et al. | Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli | |
Gileadi | Recombinant protein expression in E. coli: a historical perspective | |
Melcher | A modular set of prokaryotic and eukaryotic expression vectors | |
Herzberg et al. | SPINE: a method for the rapid detection and analysis of protein–protein interactions in vivo | |
JP6802349B2 (ja) | アルカリ耐性が向上した変異型免疫グロブリン結合タンパク質 | |
NO309153B1 (no) | Fremgangsmåte for ökning ved sekresjon av disulfidbrodannede proteiner | |
US20080206811A1 (en) | Process For Producing Polypeptide | |
Xiong et al. | Solubility of disulfide-bonded proteins in the cytoplasm of Escherichia coli and its “oxidizing” mutant | |
US6750042B2 (en) | Metal binding proteins, recombinant host cells and methods | |
Hellebust et al. | Interaction between heat shock protein DnaK and recombinant staphylococcal protein A | |
Waeber et al. | The glucose transporter of Escherichia coli: Purification and characterization by Ni+ chelate affinity chromatography of the IIBCGlc subunit | |
Dutta et al. | Protein purification by affinity chromatography | |
Park et al. | Plasmid display for stabilization of enzymes inside the cell to improve whole-cell biotransformation efficiency | |
US20070169223A1 (en) | Non-denaturing process to purify recombinant proteins from plants | |
Xu et al. | Stability of plasmid and expression of a recombinant gonadotropin-releasing hormone (GnRH) vaccine in Escherichia coli | |
JP2584697B2 (ja) | IgG精製用組換え型プロテインA | |
Jonak | Bacterial elongation factors EF-Tu, their mutants, chimeric forms, and domains: isolation and purification | |
JP2971290B2 (ja) | プラスミド及びそれで形質転換されたエシェリチア・コリ | |
EP2121726A1 (en) | Protein particles | |
Wu et al. | Design, production, and characterization of an engineered biotin ligase (BirA) and its application for affinity purification of staphylokinase produced from Bacillus subtilis via secretion | |
JP2519136B2 (ja) | 分子量マ−カ− | |
JPH04330285A (ja) | エンドウのフェニルアラニンアンモニアリアーゼ 遺伝子及びその用途 | |
US20100151518A1 (en) | Vectors and methods for enzyme production | |
JP2008119014A (ja) | プロテインキナーゼを組換え産生および精製するための改善された方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992916247 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992916247 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: CA Ref document number: 2140890 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 406809 Date of ref document: 19950320 Kind code of ref document: A Format of ref document f/p: F |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992916247 Country of ref document: EP |